South African-Japanese JV expands pharma capacity in India
Tokyo-headquartered Meiji Seika Pharma Co Ltd is to construct a new manufacturing facility at Adcock Ingram Ltd in Bengaluru to enhance its production capacity of the contract manufacturing organization (CMO) business.
Adcock Ingram, established in 2007, is a joint venture between Adcock Ingram Holdings in South Africa and Bengaluru-headquartered Medreich Ltd, a wholly-owned subsidiary of Meiji Seika Pharma.
It manufactures pharmaceutical products by under contracts and distributes in the South African, European and Oceanian markets.
By adding the new manufacturing facility, it can manufacture pharmaceutical products not only for the Adcock Ingram Group, but also for other clients. The new manufacturing facility is scheduled to start operation in March 2023, said Meiji Seika Pharma in a release on 8 Nov 2021.
The Meiji Group’s Pharmaceutical Segment, in its “2023 Medium-Term Business Plan”, has set an agenda to “Expand CMO/CDMO business” in its business strategies.
It will continue to optimize production bases in Japan and overseas to strengthen our production system and establish a system for the stable supply of highly reliable pharmaceuticals and contribute to improving access to pharmaceuticals for people over the world.
Founded in 1891, Adcock Ingram Holdings manufactures, markets and distributes a wide range of healthcare and consumer products, and is a leading supplier to both the private and public sectors of the market. #manufacturing #investment #exports #health /fiinews.com
